{"title":"México Best Sellers","description":null,"products":[{"product_id":"retatrutide","title":"Retatrutide","description":"\u003c!-- ================================================\n     MVLabs.mx — Blog Post: Retatrutide Research Guide\n     Shopify-compatible body HTML\n     ================================================ --\u003e\n\u003cmeta charset=\"UTF-8\"\u003e\n\n\u003cstyle\u003e\n\/* ── Base ───────────────────────────────────────── *\/\n:root {\n  --mv-dark:    #0b3347;\n  --mv-primary: #0e4f68;\n  --mv-mid:     #2590b4;\n  --mv-light:   #5ab4cc;\n  --mv-pale:    #cce8f2;\n  --mv-ice:     #e8f5fa;\n  --mv-text:    #0a1e2c;\n  --mv-muted:   #456d80;\n  --mv-warn:    #b45309;\n  --mv-warn-bg: #fffbeb;\n  --radius:     14px;\n  --shadow:     0 4px 24px rgba(11,51,71,0.10);\n}\n.reta-page {\n  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;\n  color: var(--mv-text);\n  max-width: 860px;\n  margin: 0 auto;\n  padding: 0 16px 60px;\n  line-height: 1.7;\n}\n.reta-page *, .reta-page *::before, .reta-page *::after { box-sizing: border-box; }\n\n\/* ── Hero ───────────────────────────────────────── *\/\n.reta-hero {\n  background: linear-gradient(135deg, var(--mv-dark) 0%, var(--mv-primary) 60%, var(--mv-mid) 100%);\n  border-radius: var(--radius);\n  padding: 48px 36px 40px;\n  margin-bottom: 32px;\n  color: #fff;\n  position: relative;\n  overflow: hidden;\n}\n.reta-hero::before {\n  content: '';\n  position: absolute; inset: 0;\n  background: url(\"data:image\/svg+xml,%3Csvg width='60' height='60' viewBox='0 0 60 60' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cg fill='none' fill-rule='evenodd'%3E%3Cg fill='%23ffffff' fill-opacity='0.04'%3E%3Cpolygon points='30,5 55,18 55,42 30,55 5,42 5,18'\/%3E%3C\/g%3E%3C\/g%3E%3C\/svg%3E\");\n  pointer-events: none;\n}\n.reta-hero-badge {\n  display: inline-flex; align-items: center; gap: 6px;\n  background: rgba(255,255,255,0.15); border: 1px solid rgba(255,255,255,0.25);\n  border-radius: 20px; padding: 4px 14px; font-size: 12px; font-weight: 600;\n  letter-spacing: 0.06em; text-transform: uppercase; margin-bottom: 16px;\n}\n.reta-hero h1 {\n  font-size: clamp(26px, 5vw, 42px); font-weight: 900;\n  letter-spacing: -0.03em; margin: 0 0 12px; line-height: 1.1;\n}\n.reta-hero p {\n  font-size: 16px; opacity: 0.88; max-width: 560px; margin: 0 0 20px;\n}\n.reta-hero-meta {\n  display: flex; flex-wrap: wrap; gap: 16px; font-size: 13px; opacity: 0.75;\n}\n.reta-hero-meta span { display: flex; align-items: center; gap: 5px; }\n\n\/* ── Research Warning Banner ─────────────────────── *\/\n.reta-warn {\n  background: var(--mv-warn-bg); border: 1.5px solid #fcd34d;\n  border-left: 5px solid var(--mv-warn);\n  border-radius: var(--radius); padding: 16px 20px; margin-bottom: 28px;\n  font-size: 13.5px; color: #92400e; line-height: 1.6;\n}\n.reta-warn strong { color: #78350f; }\n\n\/* ── Collapsible sections ─────────────────────────── *\/\n.reta-section {\n  background: #fff; border: 1.5px solid var(--mv-pale);\n  border-radius: var(--radius); margin-bottom: 16px;\n  box-shadow: 0 2px 8px rgba(11,51,71,0.06);\n  overflow: hidden;\n}\n.reta-section \u003e details \u003e summary,\n.reta-section \u003e summary {\n  display: flex; align-items: center; justify-content: space-between;\n  padding: 20px 24px; cursor: pointer; user-select: none;\n  list-style: none; gap: 12px;\n}\n.reta-section \u003e details \u003e summary::-webkit-details-marker { display: none; }\n.reta-section \u003e details \u003e summary::marker { display: none; }\n.sec-header {\n  display: flex; align-items: center; gap: 12px;\n}\n.sec-icon {\n  width: 36px; height: 36px; border-radius: 10px; flex-shrink: 0;\n  background: var(--mv-ice); display: flex; align-items: center; justify-content: center;\n}\n.sec-icon svg { color: var(--mv-primary); }\n.sec-title { font-size: 16px; font-weight: 700; color: var(--mv-primary); }\n.sec-subtitle { font-size: 12px; color: var(--mv-muted); margin-top: 2px; }\n.sec-arrow {\n  width: 22px; height: 22px; flex-shrink: 0; color: var(--mv-mid);\n  transition: transform 0.25s;\n}\ndetails[open] .sec-arrow { transform: rotate(180deg); }\n.sec-body { padding: 0 24px 24px; }\n.sec-divider { height: 1.5px; background: var(--mv-pale); margin: 0 24px 20px; }\n\/* ── Typography inside sections ──────────────────── *\/\n.reta-page h2 { font-size: 20px; font-weight: 800; color: var(--mv-dark); margin: 0 0 14px; }\n.reta-page h3 { font-size: 15px; font-weight: 700; color: var(--mv-primary); margin: 20px 0 8px; }\n.reta-page p  { margin: 0 0 14px; font-size: 14.5px; }\n.reta-page ul, .reta-page ol { margin: 0 0 14px; padding-left: 20px; }\n.reta-page li { margin-bottom: 6px; font-size: 14.5px; }\n.reta-page a  { color: var(--mv-mid); text-decoration: underline; text-decoration-thickness: 1px; }\n.reta-page a:hover { color: var(--mv-primary); }\n\n\/* ── Key stat cards ──────────────────────────────── *\/\n.stat-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(140px, 1fr)); gap: 12px; margin: 16px 0 20px; }\n.stat-card {\n  background: var(--mv-ice); border: 1.5px solid var(--mv-pale);\n  border-radius: 12px; padding: 16px 14px; text-align: center;\n}\n.stat-val { font-size: 28px; font-weight: 900; color: var(--mv-primary); line-height: 1; margin-bottom: 4px; }\n.stat-lbl { font-size: 11px; color: var(--mv-muted); font-weight: 600; text-transform: uppercase; letter-spacing: 0.05em; }\n.stat-sub { font-size: 10px; color: var(--mv-muted); margin-top: 3px; }\n\n\/* ── Chart container ─────────────────────────────── *\/\n.chart-wrap {\n  background: var(--mv-ice); border: 1.5px solid var(--mv-pale);\n  border-radius: 12px; padding: 20px 16px; margin: 16px 0;\n  overflow-x: auto;\n}\n.chart-title { font-size: 12px; font-weight: 700; color: var(--mv-muted); text-transform: uppercase; letter-spacing: 0.06em; margin-bottom: 14px; }\n.chart-source { font-size: 10px; color: var(--mv-muted); margin-top: 8px; text-align: right; }\n\n\/* ── Dosing table ─────────────────────────────────── *\/\n.dose-table { width: 100%; border-collapse: collapse; font-size: 13.5px; margin: 12px 0; }\n.dose-table th { background: var(--mv-primary); color: #fff; padding: 10px 12px; text-align: left; font-size: 11.5px; text-transform: uppercase; letter-spacing: 0.06em; }\n.dose-table th:first-child { border-radius: 8px 0 0 0; }\n.dose-table th:last-child  { border-radius: 0 8px 0 0; }\n.dose-table td { padding: 9px 12px; border-bottom: 1px solid var(--mv-pale); }\n.dose-table tr:last-child td { border-bottom: none; }\n.dose-table tr:nth-child(even) td { background: var(--mv-ice); }\n.dose-table .phase-col { font-weight: 600; color: var(--mv-primary); }\n.dose-table .max-row td { background: #e0f2fe !important; font-weight: 700; color: var(--mv-dark); }\n\n\/* ── Recon box ────────────────────────────────────── *\/\n.recon-box {\n  background: linear-gradient(135deg, var(--mv-dark), var(--mv-primary));\n  border-radius: 12px; padding: 20px 22px; color: #fff; margin: 16px 0;\n}\n.recon-box h3 { color: #fff; margin-top: 0; font-size: 14px; opacity: 0.85; text-transform: uppercase; letter-spacing: 0.07em; }\n.recon-formula { font-size: 20px; font-weight: 800; margin: 8px 0; letter-spacing: -0.01em; }\n.recon-detail { font-size: 13px; opacity: 0.8; }\n\n\/* ── Calculator CTA ──────────────────────────────── *\/\n.calc-cta {\n  background: linear-gradient(135deg, var(--mv-primary), var(--mv-mid));\n  border-radius: var(--radius); padding: 24px 28px;\n  display: flex; align-items: center; justify-content: space-between;\n  flex-wrap: wrap; gap: 16px; margin: 24px 0; text-decoration: none !important;\n}\n.calc-cta-text { color: #fff; }\n.calc-cta-text strong { display: block; font-size: 16px; font-weight: 800; margin-bottom: 4px; }\n.calc-cta-text span { font-size: 13px; opacity: 0.85; }\n.calc-cta-btn {\n  background: #fff; color: var(--mv-primary); font-weight: 800; font-size: 13px;\n  border-radius: 10px; padding: 10px 20px; white-space: nowrap; flex-shrink: 0;\n}\n\n\/* ── Side effects bar ─────────────────────────────── *\/\n.se-bar-wrap { margin: 6px 0 12px; }\n.se-bar-row { display: flex; align-items: center; gap: 10px; margin-bottom: 8px; font-size: 13px; }\n.se-bar-label { width: 120px; flex-shrink: 0; color: var(--mv-text); }\n.se-bar-track { flex: 1; background: var(--mv-pale); border-radius: 20px; height: 8px; overflow: hidden; }\n.se-bar-fill { height: 100%; border-radius: 20px; background: var(--mv-mid); }\n.se-bar-pct { width: 36px; flex-shrink: 0; color: var(--mv-muted); font-weight: 600; font-size: 12px; text-align: right; }\n\n\/* ── Reference chip ──────────────────────────────── *\/\n.ref-chip {\n  display: inline-flex; align-items: center; gap: 5px;\n  background: var(--mv-ice); border: 1px solid var(--mv-pale);\n  border-radius: 20px; padding: 3px 10px; font-size: 11px; color: var(--mv-muted);\n  text-decoration: none; vertical-align: middle; margin: 2px 2px;\n  transition: background 0.15s;\n}\n.ref-chip:hover { background: var(--mv-pale); color: var(--mv-primary); }\n\n\/* ── Footnotes ────────────────────────────────────── *\/\n.reta-footnotes {\n  border-top: 2px solid var(--mv-pale); margin-top: 40px; padding-top: 24px;\n}\n.reta-footnotes h4 { font-size: 12px; text-transform: uppercase; letter-spacing: 0.08em; color: var(--mv-muted); margin: 0 0 14px; }\n.fn-list { list-style: none; padding: 0; margin: 0; }\n.fn-list li { font-size: 12px; color: var(--mv-muted); margin-bottom: 8px; padding-left: 24px; position: relative; line-height: 1.5; }\n.fn-list li::before { content: attr(data-n); position: absolute; left: 0; font-weight: 700; color: var(--mv-mid); }\n.fn-list a { color: var(--mv-mid); }\nsup.fn { font-size: 10px; color: var(--mv-mid); font-weight: 700; cursor: default; }\n\n\/* ── Responsive ──────────────────────────────────── *\/\n@media (max-width: 600px) {\n  .reta-hero { padding: 32px 20px 28px; }\n  .sec-body { padding: 0 16px 20px; }\n  .reta-section \u003e details \u003e summary { padding: 16px 18px; }\n  .calc-cta { flex-direction: column; }\n  .stat-grid { grid-template-columns: repeat(2, 1fr); }\n}\n\u003c\/style\u003e\n\n\u003cdiv class=\"reta-page\"\u003e\n\n  \u003c!-- ── Hero ────────────────────────────────────────── --\u003e\n  \u003cdiv class=\"reta-hero\"\u003e\n    \u003cdiv class=\"reta-hero-badge\"\u003e\n      \u003csvg width=\"12\" height=\"12\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"M9 3H5a2 2 0 0 0-2 2v4\"\u003e\u003c\/path\u003e\u003cpath d=\"M9 3h6\"\u003e\u003c\/path\u003e\u003cpath d=\"M15 3h4a2 2 0 0 1 2 2v4\"\u003e\u003c\/path\u003e\u003cpath d=\"M3 9v6\"\u003e\u003c\/path\u003e\u003cpath d=\"M21 9v6\"\u003e\u003c\/path\u003e\u003cpath d=\"M3 15v4a2 2 0 0 0 2 2h4\"\u003e\u003c\/path\u003e\u003cpath d=\"M15 21h4a2 2 0 0 0 2-2v-4\"\u003e\u003c\/path\u003e\u003cpath d=\"M9 21h6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\n      Research Reference — MVLabs.mx\n    \u003c\/div\u003e\n    \u003ch1\u003eRetatrutide (LY3437943)\u003c\/h1\u003e\n    \u003cp\u003eThe first triple hormone receptor agonist targeting GLP-1, GIP, and Glucagon receptors simultaneously — delivering bariatric-level weight loss in research settings.\u003c\/p\u003e\n    \u003cdiv class=\"reta-hero-meta\"\u003e\n      \u003cspan\u003e📋 Research use only\u003c\/span\u003e\n      \u003cspan\u003e🔬 Phase 3 data available\u003c\/span\u003e\n      \u003cspan\u003e💊 10 mg \/ vial · SKU: RT10\u003c\/span\u003e\n      \u003cspan\u003e📅 Updated June 2026\u003c\/span\u003e\n    \u003c\/div\u003e\n  \u003c\/div\u003e\n  \u003c!-- ── Research Disclaimer ─────────────────────────── --\u003e\n  \u003cdiv class=\"reta-warn\"\u003e\n    \u003cstrong\u003e⚠ For Research Purposes Only.\u003c\/strong\u003e All protocols, dosing information, and data on this page are provided exclusively for educational and scientific research reference. Retatrutide (LY3437943) is an investigational compound. It is \u003cstrong\u003enot approved by the FDA or any regulatory authority\u003c\/strong\u003e for human use. All dosing ranges referenced are derived from published clinical research. MVLabs.mx products are strictly for in-vitro and research use only. Always consult a qualified medical professional.\n  \u003c\/div\u003e\n\n  \u003c!-- ── Section 1: What Is Retatrutide ─────────────── --\u003e\n  \u003cdiv class=\"reta-section\"\u003e\n    \u003cdetails open\u003e\n      \u003csummary\u003e\n        \u003cdiv class=\"sec-header\"\u003e\n          \u003cdiv class=\"sec-icon\"\u003e\u003csvg width=\"18\" height=\"18\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\u003ccircle cx=\"12\" cy=\"12\" r=\"10\"\u003e\u003c\/circle\u003e\u003cpath d=\"M12 16v-4\"\u003e\u003c\/path\u003e\u003cpath d=\"M12 8h.01\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/div\u003e\n          \u003cdiv\u003e\n            \u003cdiv class=\"sec-title\"\u003eWhat Is Retatrutide?\u003c\/div\u003e\n            \u003cdiv class=\"sec-subtitle\"\u003eOverview, molecular class \u0026amp; development status\u003c\/div\u003e\n          \u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003csvg class=\"sec-arrow\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\n      \u003c\/summary\u003e\n      \u003cdiv class=\"sec-divider\"\u003e\u003c\/div\u003e\n      \u003cdiv class=\"sec-body\"\u003e\n        \u003cp\u003eRetatrutide (developmental code \u003cstrong\u003eLY3437943\u003c\/strong\u003e) is a synthetic single-peptide molecule developed by \u003cstrong\u003eEli Lilly and Company\u003c\/strong\u003e. It is the world's first \u003cstrong\u003etriple receptor agonist\u003c\/strong\u003e — simultaneously activating glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.\u003csup class=\"fn\"\u003e[1]\u003c\/sup\u003e\u003c\/p\u003e\n        \u003cp\u003eUnlike semaglutide (GLP-1 only) or tirzepatide (GLP-1\/GIP dual agonist), retatrutide adds glucagon receptor activation, which drives direct thermogenesis and hepatic fat mobilization beyond what satiety-based mechanisms alone can achieve.\u003csup class=\"fn\"\u003e[2]\u003c\/sup\u003e\u003c\/p\u003e\n        \u003ch3\u003eReceptor Targets \u0026amp; Their Roles\u003c\/h3\u003e\n        \u003cdiv class=\"chart-wrap\"\u003e\n          \u003cdiv class=\"chart-title\"\u003eTriple Receptor Mechanism\u003c\/div\u003e\n          \u003csvg viewbox=\"0 0 680 220\" width=\"100%\" style=\"display:block;max-width:680px;margin:0 auto;font-family:Arial,sans-serif;\"\u003e\n            \u003cellipse cx=\"340\" cy=\"110\" rx=\"62\" ry=\"38\" fill=\"#0e4f68\" stroke=\"#2590b4\" stroke-width=\"2\"\u003e\u003c\/ellipse\u003e\n            \u003ctext x=\"340\" y=\"106\" text-anchor=\"middle\" font-size=\"13\" font-weight=\"800\" fill=\"#fff\"\u003eRETA\u003c\/text\u003e\n            \u003ctext x=\"340\" y=\"122\" text-anchor=\"middle\" font-size=\"10\" fill=\"#9dd4e4\"\u003eLY3437943\u003c\/text\u003e\n            \u003cellipse cx=\"100\" cy=\"60\" rx=\"80\" ry=\"34\" fill=\"#e2f5fa\" stroke=\"#2590b4\" stroke-width=\"1.5\"\u003e\u003c\/ellipse\u003e\n            \u003ctext x=\"100\" y=\"55\" text-anchor=\"middle\" font-size=\"12\" font-weight=\"700\" fill=\"#0e4f68\"\u003eGLP-1R\u003c\/text\u003e\n            \u003ctext x=\"100\" y=\"70\" text-anchor=\"middle\" font-size=\"10\" fill=\"#456d80\"\u003eAppetite ↓ · Insulin ↑\u003c\/text\u003e\n            \u003cellipse cx=\"340\" cy=\"32\" rx=\"80\" ry=\"28\" fill=\"#e2f5fa\" stroke=\"#2590b4\" stroke-width=\"1.5\"\u003e\u003c\/ellipse\u003e\n            \u003ctext x=\"340\" y=\"26\" text-anchor=\"middle\" font-size=\"12\" font-weight=\"700\" fill=\"#0e4f68\"\u003eGIPR\u003c\/text\u003e\n            \u003ctext x=\"340\" y=\"42\" text-anchor=\"middle\" font-size=\"10\" fill=\"#456d80\"\u003eInsulin ↑ · Nausea ↓\u003c\/text\u003e\n            \u003cellipse cx=\"580\" cy=\"60\" rx=\"80\" ry=\"34\" fill=\"#e2f5fa\" stroke=\"#2590b4\" stroke-width=\"1.5\"\u003e\u003c\/ellipse\u003e\n            \u003ctext x=\"580\" y=\"55\" text-anchor=\"middle\" font-size=\"12\" font-weight=\"700\" fill=\"#0e4f68\"\u003eGCGR\u003c\/text\u003e\n            \u003ctext x=\"580\" y=\"70\" text-anchor=\"middle\" font-size=\"10\" fill=\"#456d80\"\u003eEnergy ↑ · Fat burn ↑\u003c\/text\u003e\n            \u003cline x1=\"282\" y1=\"88\" x2=\"178\" y2=\"72\" stroke=\"#2590b4\" stroke-width=\"1.8\" stroke-dasharray=\"4,3\" marker-end=\"url(#ar)\"\u003e\u003c\/line\u003e\n            \u003cline x1=\"320\" y1=\"73\" x2=\"335\" y2=\"60\" stroke=\"#2590b4\" stroke-width=\"1.8\" stroke-dasharray=\"4,3\" marker-end=\"url(#ar)\"\u003e\u003c\/line\u003e\n            \u003cline x1=\"398\" y1=\"88\" x2=\"502\" y2=\"72\" stroke=\"#2590b4\" stroke-width=\"1.8\" stroke-dasharray=\"4,3\" marker-end=\"url(#ar)\"\u003e\u003c\/line\u003e\n            \u003cdefs\u003e\u003cmarker id=\"ar\" markerwidth=\"6\" markerheight=\"6\" refx=\"5\" refy=\"3\" orient=\"auto\"\u003e\u003cpath d=\"M0,0 L0,6 L6,3 z\" fill=\"#2590b4\"\u003e\u003c\/path\u003e\u003c\/marker\u003e\u003c\/defs\u003e\n            \u003crect x=\"160\" y=\"162\" width=\"360\" height=\"46\" rx=\"10\" fill=\"#0e4f68\"\u003e\u003c\/rect\u003e\n            \u003ctext x=\"340\" y=\"181\" text-anchor=\"middle\" font-size=\"12\" font-weight=\"700\" fill=\"#fff\"\u003eCombined Effect\u003c\/text\u003e\n            \u003ctext x=\"340\" y=\"198\" text-anchor=\"middle\" font-size=\"11\" fill=\"#9dd4e4\"\u003eWeight loss · Improved glycemic control · Reduced visceral fat\u003c\/text\u003e\n            \u003cline x1=\"340\" y1=\"148\" x2=\"340\" y2=\"162\" stroke=\"#2590b4\" stroke-width=\"1.5\" marker-end=\"url(#ar)\"\u003e\u003c\/line\u003e\n          \u003c\/svg\u003e\n          \u003cdiv class=\"chart-source\"\u003eAdapted from: Jastreboff et al., NEJM 2023; Nature Cell Discovery 2024 \u003csup class=\"fn\"\u003e[1,3]\u003c\/sup\u003e\n\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eDevelopment Timeline\u003c\/h3\u003e\n        \u003cul\u003e\n          \u003cli\u003e\n\u003cstrong\u003e2021:\u003c\/strong\u003e Phase 1 first-in-human study initiated (NCT04881760)\u003c\/li\u003e\n          \u003cli\u003e\n\u003cstrong\u003eJune 2023:\u003c\/strong\u003e Phase 2 results published in \u003cem\u003eNew England Journal of Medicine\u003c\/em\u003e\n\u003c\/li\u003e\n          \u003cli\u003e\n\u003cstrong\u003e2024–2026:\u003c\/strong\u003e Phase 3 TRIUMPH program (5 trials)\u003c\/li\u003e\n          \u003cli\u003e\n\u003cstrong\u003e2025:\u003c\/strong\u003e TRIUMPH-1 topline: up to \u003cstrong\u003e30.3%\u003c\/strong\u003e weight loss at 104 weeks\u003c\/li\u003e\n          \u003cli\u003e\n\u003cstrong\u003eFDA Approval:\u003c\/strong\u003e Pending (NDA submission expected late 2026)\u003c\/li\u003e\n        \u003c\/ul\u003e\n        \u003cdiv style=\"display:flex;gap:8px;flex-wrap:wrap;margin-top:12px;\"\u003e\n          \u003ca class=\"ref-chip\" href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e📄 NEJM Phase 2 Paper\u003c\/a\u003e\n          \u003ca class=\"ref-chip\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT04881760\" target=\"_blank\" rel=\"noopener\"\u003e🔬 ClinicalTrials.gov\u003c\/a\u003e\n          \u003ca class=\"ref-chip\" href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss\" target=\"_blank\" rel=\"noopener\"\u003e🏢 Lilly TRIUMPH-1\u003c\/a\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/details\u003e\n  \u003c\/div\u003e\n  \u003c!-- ── Section 2: Clinical Evidence ───────────────── --\u003e\n  \u003cdiv class=\"reta-section\"\u003e\n    \u003cdetails\u003e\n      \u003csummary\u003e\n        \u003cdiv class=\"sec-header\"\u003e\n          \u003cdiv class=\"sec-icon\"\u003e\u003csvg width=\"18\" height=\"18\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\u003cpath d=\"M3 3v18h18\"\u003e\u003c\/path\u003e\u003cpath d=\"m19 9-5 5-4-4-3 3\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/div\u003e\n          \u003cdiv\u003e\n\u003cdiv class=\"sec-title\"\u003eClinical Evidence\u003c\/div\u003e\n\u003cdiv class=\"sec-subtitle\"\u003ePhase 2 \u0026amp; Phase 3 TRIUMPH trial data\u003c\/div\u003e\n\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003csvg class=\"sec-arrow\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\n      \u003c\/summary\u003e\n      \u003cdiv class=\"sec-divider\"\u003e\u003c\/div\u003e\n      \u003cdiv class=\"sec-body\"\u003e\n        \u003cdiv class=\"stat-grid\"\u003e\n          \u003cdiv class=\"stat-card\"\u003e\n\u003cdiv class=\"stat-val\"\u003e30.3%\u003c\/div\u003e\n\u003cdiv class=\"stat-lbl\"\u003eMax weight loss\u003c\/div\u003e\n\u003cdiv class=\"stat-sub\"\u003ePhase 3 · 104 weeks\u003c\/div\u003e\n\u003c\/div\u003e\n          \u003cdiv class=\"stat-card\"\u003e\n\u003cdiv class=\"stat-val\"\u003e70.3 lb\u003c\/div\u003e\n\u003cdiv class=\"stat-lbl\"\u003eAvg. lost (12 mg)\u003c\/div\u003e\n\u003cdiv class=\"stat-sub\"\u003eTRIUMPH-1 · 80 wks\u003c\/div\u003e\n\u003c\/div\u003e\n          \u003cdiv class=\"stat-card\"\u003e\n\u003cdiv class=\"stat-val\"\u003e2,339\u003c\/div\u003e\n\u003cdiv class=\"stat-lbl\"\u003eParticipants\u003c\/div\u003e\n\u003cdiv class=\"stat-sub\"\u003eTRIUMPH-1 trial\u003c\/div\u003e\n\u003c\/div\u003e\n          \u003cdiv class=\"stat-card\"\u003e\n\u003cdiv class=\"stat-val\"\u003e3×\u003c\/div\u003e\n\u003cdiv class=\"stat-lbl\"\u003eReceptor targets\u003c\/div\u003e\n\u003cdiv class=\"stat-sub\"\u003eGLP-1 · GIP · Glucagon\u003c\/div\u003e\n\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003ePhase 2 — Weight Loss by Dose (48 Weeks)\u003csup class=\"fn\"\u003e[1]\u003c\/sup\u003e\n\u003c\/h3\u003e\n        \u003cdiv class=\"chart-wrap\"\u003e\n          \u003cdiv class=\"chart-title\"\u003eMean % Body Weight Change at 48 Weeks — Phase 2 (Jastreboff et al., NEJM 2023)\u003c\/div\u003e\n          \u003csvg viewbox=\"0 0 580 200\" width=\"100%\" style=\"display:block;font-family:Arial,sans-serif;\"\u003e\n            \u003cline x1=\"60\" y1=\"20\" x2=\"60\" y2=\"155\" stroke=\"#c0d9e4\" stroke-width=\"1\"\u003e\u003c\/line\u003e\n            \u003cline x1=\"60\" y1=\"155\" x2=\"555\" y2=\"155\" stroke=\"#c0d9e4\" stroke-width=\"1\"\u003e\u003c\/line\u003e\n            \u003cline x1=\"60\" y1=\"118\" x2=\"555\" y2=\"118\" stroke=\"#e2f5fa\" stroke-width=\"1\" stroke-dasharray=\"4,3\"\u003e\u003c\/line\u003e\n            \u003cline x1=\"60\" y1=\"83\" x2=\"555\" y2=\"83\" stroke=\"#e2f5fa\" stroke-width=\"1\" stroke-dasharray=\"4,3\"\u003e\u003c\/line\u003e\n            \u003cline x1=\"60\" y1=\"48\" x2=\"555\" y2=\"48\" stroke=\"#e2f5fa\" stroke-width=\"1\" stroke-dasharray=\"4,3\"\u003e\u003c\/line\u003e\n            \u003ctext x=\"52\" y=\"159\" text-anchor=\"end\" font-size=\"10\" fill=\"#456d80\"\u003e0%\u003c\/text\u003e\n            \u003ctext x=\"52\" y=\"122\" text-anchor=\"end\" font-size=\"10\" fill=\"#456d80\"\u003e−5%\u003c\/text\u003e\n            \u003ctext x=\"52\" y=\"87\" text-anchor=\"end\" font-size=\"10\" fill=\"#456d80\"\u003e−15%\u003c\/text\u003e\n            \u003ctext x=\"52\" y=\"52\" text-anchor=\"end\" font-size=\"10\" fill=\"#456d80\"\u003e−25%\u003c\/text\u003e\n            \u003crect x=\"85\" y=\"143\" width=\"60\" height=\"12\" rx=\"3\" fill=\"#cce8f2\"\u003e\u003c\/rect\u003e\n            \u003ctext x=\"115\" y=\"138\" text-anchor=\"middle\" font-size=\"11\" fill=\"#456d80\"\u003e−2.1%\u003c\/text\u003e\n            \u003crect x=\"195\" y=\"108\" width=\"60\" height=\"47\" rx=\"3\" fill=\"#5ab4cc\"\u003e\u003c\/rect\u003e\n            \u003ctext x=\"225\" y=\"103\" text-anchor=\"middle\" font-size=\"11\" fill=\"#456d80\"\u003e−8.7%\u003c\/text\u003e\n            \u003crect x=\"305\" y=\"63\" width=\"60\" height=\"92\" rx=\"3\" fill=\"#2590b4\"\u003e\u003c\/rect\u003e\n            \u003ctext x=\"335\" y=\"58\" text-anchor=\"middle\" font-size=\"11\" fill=\"#0e4f68\"\u003e−17.1%\u003c\/text\u003e\n            \u003crect x=\"415\" y=\"32\" width=\"60\" height=\"123\" rx=\"3\" fill=\"#0e4f68\"\u003e\u003c\/rect\u003e\n            \u003ctext x=\"445\" y=\"27\" text-anchor=\"middle\" font-size=\"11\" fill=\"#0e4f68\"\u003e−22.8%\u003c\/text\u003e\n            \u003crect x=\"490\" y=\"25\" width=\"55\" height=\"130\" rx=\"3\" fill=\"#0b3347\"\u003e\u003c\/rect\u003e\n            \u003ctext x=\"517\" y=\"20\" text-anchor=\"middle\" font-size=\"11\" fill=\"#0b3347\"\u003e−24.2%\u003c\/text\u003e\n            \u003ctext x=\"115\" y=\"172\" text-anchor=\"middle\" font-size=\"11\" fill=\"#456d80\"\u003ePlacebo\u003c\/text\u003e\n            \u003ctext x=\"225\" y=\"172\" text-anchor=\"middle\" font-size=\"11\" fill=\"#456d80\"\u003e1 mg\u003c\/text\u003e\n            \u003ctext x=\"335\" y=\"172\" text-anchor=\"middle\" font-size=\"11\" fill=\"#456d80\"\u003e4 mg\u003c\/text\u003e\n            \u003ctext x=\"445\" y=\"172\" text-anchor=\"middle\" font-size=\"11\" fill=\"#0e4f68\"\u003e8 mg\u003c\/text\u003e\n            \u003ctext x=\"517\" y=\"172\" text-anchor=\"middle\" font-size=\"11\" fill=\"#0b3347\"\u003e12 mg\u003c\/text\u003e\n          \u003c\/svg\u003e\n          \u003cdiv class=\"chart-source\"\u003eSource: Jastreboff AM et al. N Engl J Med. 2023;389:514-526\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003evs. Competing Agents\u003c\/h3\u003e\n        \u003ctable class=\"dose-table\"\u003e\n          \u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDrug\u003c\/th\u003e\n\u003cth\u003eClass\u003c\/th\u003e\n\u003cth\u003eMax Weight Loss\u003c\/th\u003e\n\u003cth\u003eDuration\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n          \u003ctbody\u003e\n            \u003ctr\u003e\n\u003ctd\u003eSemaglutide (Wegovy)\u003c\/td\u003e\n\u003ctd\u003eGLP-1\u003c\/td\u003e\n\u003ctd\u003e−15.2%\u003c\/td\u003e\n\u003ctd\u003e68 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n            \u003ctr\u003e\n\u003ctd\u003eTirzepatide (Zepbound)\u003c\/td\u003e\n\u003ctd\u003eGLP-1\/GIP\u003c\/td\u003e\n\u003ctd\u003e−22.5%\u003c\/td\u003e\n\u003ctd\u003e72 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n            \u003ctr class=\"max-row\"\u003e\n\u003ctd\u003e\u003cstrong\u003eRetatrutide\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eGLP-1\/GIP\/Glucagon\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e−30.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e104 weeks\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n          \u003c\/tbody\u003e\n        \u003c\/table\u003e\n        \u003cdiv style=\"display:flex;gap:8px;flex-wrap:wrap;margin-top:12px;\"\u003e\n          \u003ca class=\"ref-chip\" href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e📄 NEJM Phase 2 Full Text\u003c\/a\u003e\n          \u003ca class=\"ref-chip\" href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss\" target=\"_blank\" rel=\"noopener\"\u003e📊 TRIUMPH-1 Data\u003c\/a\u003e\n        \u003c\/div\u003e\n      \u003c\/div\u003e\n    \u003c\/details\u003e\n  \u003c\/div\u003e\n\n  \u003c!-- ── Section 3: Research Dosing Protocol ────────── --\u003e\n  \u003cdiv class=\"reta-section\"\u003e\n    \u003cdetails\u003e\n      \u003csummary\u003e\n        \u003cdiv class=\"sec-header\"\u003e\n          \u003cdiv class=\"sec-icon\"\u003e\u003csvg width=\"18\" height=\"18\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\u003cpath d=\"M9 5H7a2 2 0 0 0-2 2v12a2 2 0 0 0 2 2h10a2 2 0 0 0 2-2V7a2 2 0 0 0-2-2h-2\"\u003e\u003c\/path\u003e\u003crect x=\"9\" y=\"3\" width=\"6\" height=\"4\" rx=\"1\"\u003e\u003c\/rect\u003e\u003c\/svg\u003e\u003c\/div\u003e\n          \u003cdiv\u003e\n\u003cdiv class=\"sec-title\"\u003eResearch Dosing Protocol\u003c\/div\u003e\n\u003cdiv class=\"sec-subtitle\"\u003e⚠ Research use only — not medical advice\u003c\/div\u003e\n\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003csvg class=\"sec-arrow\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\n      \u003c\/summary\u003e\n      \u003cdiv class=\"sec-divider\"\u003e\u003c\/div\u003e\n      \u003cdiv class=\"sec-body\"\u003e\n        \u003cdiv class=\"reta-warn\" style=\"margin-bottom:20px;\"\u003e\n\u003cstrong\u003eResearch Reference Only.\u003c\/strong\u003e Protocol derived from Phase 2 and Phase 3 clinical trial data. Strictly for in-vitro or pre-clinical research.\u003c\/div\u003e\n        \u003cdiv class=\"recon-box\"\u003e\n          \u003ch3\u003eReconstitution — 10 mg Vial (SKU: RT10)\u003c\/h3\u003e\n          \u003cdiv class=\"recon-formula\"\u003e10 mg + 2 mL BAC Water = 5 mg\/mL\u003c\/div\u003e\n          \u003cdiv class=\"recon-detail\"\u003e1 unit (U-100) = 0.01 mL = 50 µg  ·  Store at 2–8 °C  ·  Use within 28 days\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eEscalation Schedule (Phase 2 Protocol)\u003c\/h3\u003e\n        \u003ctable class=\"dose-table\"\u003e\n          \u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePhase\u003c\/th\u003e\n\u003cth\u003eWeekly Dose\u003c\/th\u003e\n\u003cth\u003eUnits (U-100)\u003c\/th\u003e\n\u003cth\u003eVolume\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n          \u003ctbody\u003e\n            \u003ctr\u003e\n\u003ctd class=\"phase-col\"\u003eWeeks 1–2\u003c\/td\u003e\n\u003ctd\u003e0.5 mg\u003c\/td\u003e\n\u003ctd\u003e10 U\u003c\/td\u003e\n\u003ctd\u003e0.10 mL\u003c\/td\u003e\n\u003ctd\u003ePer tolerance\u003c\/td\u003e\n\u003c\/tr\u003e\n            \u003ctr\u003e\n\u003ctd class=\"phase-col\"\u003eWeeks 3–4\u003c\/td\u003e\n\u003ctd\u003e1 mg\u003c\/td\u003e\n\u003ctd\u003e20 U\u003c\/td\u003e\n\u003ctd\u003e0.20 mL\u003c\/td\u003e\n\u003ctd\u003ePer tolerance\u003c\/td\u003e\n\u003c\/tr\u003e\n            \u003ctr\u003e\n\u003ctd class=\"phase-col\"\u003eWeeks 5–8\u003c\/td\u003e\n\u003ctd\u003e2 mg\u003c\/td\u003e\n\u003ctd\u003e40 U\u003c\/td\u003e\n\u003ctd\u003e0.40 mL\u003c\/td\u003e\n\u003ctd\u003ePer tolerance\u003c\/td\u003e\n\u003c\/tr\u003e\n            \u003ctr\u003e\n\u003ctd class=\"phase-col\"\u003eWeeks 9–12\u003c\/td\u003e\n\u003ctd\u003e4 mg\u003c\/td\u003e\n\u003ctd\u003e80 U\u003c\/td\u003e\n\u003ctd\u003e0.80 mL\u003c\/td\u003e\n\u003ctd\u003ePer tolerance\u003c\/td\u003e\n\u003c\/tr\u003e\n            \u003ctr class=\"max-row\"\u003e\n\u003ctd class=\"phase-col\"\u003eWeek 13+\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8 mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e160 U (2 syringes)\u003c\/td\u003e\n\u003ctd\u003e1.60 mL\u003c\/td\u003e\n\u003ctd\u003eMax — do not exceed\u003c\/td\u003e\n\u003c\/tr\u003e\n          \u003c\/tbody\u003e\n        \u003c\/table\u003e\n        \u003ca class=\"calc-cta\" href=\"https:\/\/mvlabs.mx\/pages\/peptide-calculator\"\u003e\n          \u003cdiv class=\"calc-cta-text\"\u003e\n\u003cstrong\u003e🧮 MVLabs.mx Peptide Calculator\u003c\/strong\u003e\u003cspan\u003eEnter your vial size and BAC water to auto-calculate units \u0026amp; volume for any dose\u003c\/span\u003e\n\u003c\/div\u003e\n          \u003cdiv class=\"calc-cta-btn\"\u003eOpen Calculator →\u003c\/div\u003e\n        \u003c\/a\u003e\n      \u003c\/div\u003e\n    \u003c\/details\u003e\n  \u003c\/div\u003e\n  \u003c!-- ── Section 4: Safety ────────── --\u003e\n  \u003cdiv class=\"reta-section\"\u003e\n    \u003cdetails\u003e\n      \u003csummary\u003e\n        \u003cdiv class=\"sec-header\"\u003e\n          \u003cdiv class=\"sec-icon\"\u003e\u003csvg width=\"18\" height=\"18\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\u003cpath d=\"M10.29 3.86 1.82 18a2 2 0 0 0 1.71 3h16.94a2 2 0 0 0 1.71-3L13.71 3.86a2 2 0 0 0-3.42 0z\"\u003e\u003c\/path\u003e\u003cline x1=\"12\" y1=\"9\" x2=\"12\" y2=\"13\"\u003e\u003c\/line\u003e\u003cline x1=\"12\" y1=\"17\" x2=\"12.01\" y2=\"17\"\u003e\u003c\/line\u003e\u003c\/svg\u003e\u003c\/div\u003e\n          \u003cdiv\u003e\n\u003cdiv class=\"sec-title\"\u003eSafety Profile \u0026amp; Tolerability\u003c\/div\u003e\n\u003cdiv class=\"sec-subtitle\"\u003ePhase 2 adverse event data — research reference\u003c\/div\u003e\n\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003csvg class=\"sec-arrow\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\n      \u003c\/summary\u003e\n      \u003cdiv class=\"sec-divider\"\u003e\u003c\/div\u003e\n      \u003cdiv class=\"sec-body\"\u003e\n        \u003cp\u003eAdverse events in Phase 2 were predominantly gastrointestinal, dose-dependent, and mostly mild-to-moderate in severity — occurring primarily during dose escalation.\u003c\/p\u003e\n        \u003ch3\u003eMost Common Adverse Events (8 mg group, Phase 2)\u003c\/h3\u003e\n        \u003cdiv class=\"se-bar-wrap\"\u003e\n          \u003cdiv class=\"se-bar-row\"\u003e\n\u003cspan class=\"se-bar-label\"\u003eNausea\u003c\/span\u003e\u003cdiv class=\"se-bar-track\"\u003e\u003cdiv class=\"se-bar-fill\" style=\"width:42%\"\u003e\u003c\/div\u003e\u003c\/div\u003e\n\u003cspan class=\"se-bar-pct\"\u003e~42%\u003c\/span\u003e\n\u003c\/div\u003e\n          \u003cdiv class=\"se-bar-row\"\u003e\n\u003cspan class=\"se-bar-label\"\u003eDiarrhea\u003c\/span\u003e\u003cdiv class=\"se-bar-track\"\u003e\u003cdiv class=\"se-bar-fill\" style=\"width:22%;background:#5ab4cc\"\u003e\u003c\/div\u003e\u003c\/div\u003e\n\u003cspan class=\"se-bar-pct\"\u003e~22%\u003c\/span\u003e\n\u003c\/div\u003e\n          \u003cdiv class=\"se-bar-row\"\u003e\n\u003cspan class=\"se-bar-label\"\u003eVomiting\u003c\/span\u003e\u003cdiv class=\"se-bar-track\"\u003e\u003cdiv class=\"se-bar-fill\" style=\"width:19%;background:#5ab4cc\"\u003e\u003c\/div\u003e\u003c\/div\u003e\n\u003cspan class=\"se-bar-pct\"\u003e~19%\u003c\/span\u003e\n\u003c\/div\u003e\n          \u003cdiv class=\"se-bar-row\"\u003e\n\u003cspan class=\"se-bar-label\"\u003eConstipation\u003c\/span\u003e\u003cdiv class=\"se-bar-track\"\u003e\u003cdiv class=\"se-bar-fill\" style=\"width:15%;background:#96cee0\"\u003e\u003c\/div\u003e\u003c\/div\u003e\n\u003cspan class=\"se-bar-pct\"\u003e~15%\u003c\/span\u003e\n\u003c\/div\u003e\n          \u003cdiv class=\"se-bar-row\"\u003e\n\u003cspan class=\"se-bar-label\"\u003eDecreased appetite\u003c\/span\u003e\u003cdiv class=\"se-bar-track\"\u003e\u003cdiv class=\"se-bar-fill\" style=\"width:32%;background:#0e4f68\"\u003e\u003c\/div\u003e\u003c\/div\u003e\n\u003cspan class=\"se-bar-pct\"\u003e~32%\u003c\/span\u003e\n\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eKey Safety Notes\u003c\/h3\u003e\n        \u003cul\u003e\n          \u003cli\u003eGI adverse events primarily occur during dose escalation — not at steady state\u003c\/li\u003e\n          \u003cli\u003eNo significant hypoglycemia in non-diabetic subjects\u003c\/li\u003e\n          \u003cli\u003eHeart rate increase: +2–4 bpm at higher doses\u003c\/li\u003e\n          \u003cli\u003eNo serious pancreatitis events in Phase 2\u003c\/li\u003e\n          \u003cli\u003eDiscontinuation rates: 6–16% depending on dose\u003c\/li\u003e\n        \u003c\/ul\u003e\n      \u003c\/div\u003e\n    \u003c\/details\u003e\n  \u003c\/div\u003e\n\n  \u003c!-- ── Section 5: Reconstitution ──────────────────── --\u003e\n  \u003cdiv class=\"reta-section\"\u003e\n    \u003cdetails\u003e\n      \u003csummary\u003e\n        \u003cdiv class=\"sec-header\"\u003e\n          \u003cdiv class=\"sec-icon\"\u003e\u003csvg width=\"18\" height=\"18\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\u003cpath d=\"M14.5 2H6a2 2 0 0 0-2 2v16a2 2 0 0 0 2 2h12a2 2 0 0 0 2-2V7.5L14.5 2z\"\u003e\u003c\/path\u003e\u003cpolyline points=\"14 2 14 8 20 8\"\u003e\u003c\/polyline\u003e\u003c\/svg\u003e\u003c\/div\u003e\n          \u003cdiv\u003e\n\u003cdiv class=\"sec-title\"\u003eReconstitution \u0026amp; Storage Guide\u003c\/div\u003e\n\u003cdiv class=\"sec-subtitle\"\u003eStep-by-step lab preparation reference\u003c\/div\u003e\n\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003csvg class=\"sec-arrow\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\n      \u003c\/summary\u003e\n      \u003cdiv class=\"sec-divider\"\u003e\u003c\/div\u003e\n      \u003cdiv class=\"sec-body\"\u003e\n        \u003cdiv class=\"recon-box\"\u003e\n          \u003ch3\u003eStandard Reconstitution\u003c\/h3\u003e\n          \u003cdiv class=\"recon-formula\"\u003e10 mg vial + 2 mL Bacteriostatic Water\u003c\/div\u003e\n          \u003cdiv class=\"recon-detail\"\u003e= 5 mg\/mL (5,000 µg\/mL)  ·  1 U-100 unit = 50 µg  ·  1 mL = 5 mg\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003ch3\u003eStep-by-Step Procedure\u003c\/h3\u003e\n        \u003col\u003e\n          \u003cli\u003eAllow the lyophilized vial to reach room temperature (~15 min)\u003c\/li\u003e\n          \u003cli\u003eClean rubber stoppers with 70% isopropyl alcohol\u003c\/li\u003e\n          \u003cli\u003eDraw 2.0 mL of bacteriostatic water into a clean 3 mL syringe\u003c\/li\u003e\n          \u003cli\u003eInject water \u003cstrong\u003eslowly down the side\u003c\/strong\u003e — do not spray onto powder\u003c\/li\u003e\n          \u003cli\u003eGently swirl (no vortex\/shake) until dissolved — clear and colorless\u003c\/li\u003e\n          \u003cli\u003eDiscard if cloudiness or particles visible\u003c\/li\u003e\n          \u003cli\u003eLabel with reconstitution date, store at \u003cstrong\u003e2–8 °C\u003c\/strong\u003e\n\u003c\/li\u003e\n        \u003c\/ol\u003e\n        \u003ch3\u003eStorage Conditions\u003c\/h3\u003e\n        \u003ctable class=\"dose-table\"\u003e\n          \u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eState\u003c\/th\u003e\n\u003cth\u003eTemperature\u003c\/th\u003e\n\u003cth\u003eShelf Life\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n          \u003ctbody\u003e\n            \u003ctr\u003e\n\u003ctd\u003eLyophilized (powder)\u003c\/td\u003e\n\u003ctd\u003e−20 °C (freezer)\u003c\/td\u003e\n\u003ctd\u003e12–24 months\u003c\/td\u003e\n\u003ctd\u003eKeep desiccated \u0026amp; dark\u003c\/td\u003e\n\u003c\/tr\u003e\n            \u003ctr\u003e\n\u003ctd\u003eLyophilized (powder)\u003c\/td\u003e\n\u003ctd\u003e2–8 °C (fridge)\u003c\/td\u003e\n\u003ctd\u003e3–6 months\u003c\/td\u003e\n\u003ctd\u003eAvoid freeze-thaw cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n            \u003ctr class=\"max-row\"\u003e\n\u003ctd\u003e\u003cstrong\u003eReconstituted\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2–8 °C (fridge)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e28 days\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eDo not freeze\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n          \u003c\/tbody\u003e\n        \u003c\/table\u003e\n        \u003ca class=\"calc-cta\" href=\"https:\/\/mvlabs.mx\/pages\/peptide-calculator\"\u003e\n          \u003cdiv class=\"calc-cta-text\"\u003e\n\u003cstrong\u003e🧮 Calculate Your Dose\u003c\/strong\u003e\u003cspan\u003eUse the MVLabs.mx Peptide Calculator to convert mg doses to syringe units instantly\u003c\/span\u003e\n\u003c\/div\u003e\n          \u003cdiv class=\"calc-cta-btn\"\u003eOpen Calculator →\u003c\/div\u003e\n        \u003c\/a\u003e\n      \u003c\/div\u003e\n    \u003c\/details\u003e\n  \u003c\/div\u003e\n\n  \u003c!-- ── Section 6: Literature ────────── --\u003e\n  \u003cdiv class=\"reta-section\"\u003e\n    \u003cdetails\u003e\n      \u003csummary\u003e\n        \u003cdiv class=\"sec-header\"\u003e\n          \u003cdiv class=\"sec-icon\"\u003e\u003csvg width=\"18\" height=\"18\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\u003cpath d=\"M4 19.5v-15A2.5 2.5 0 0 1 6.5 2H20v20H6.5a2.5 2.5 0 0 1 0-5H20\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/div\u003e\n          \u003cdiv\u003e\n\u003cdiv class=\"sec-title\"\u003eResearch Literature \u0026amp; Official Sources\u003c\/div\u003e\n\u003cdiv class=\"sec-subtitle\"\u003ePeer-reviewed studies, Lilly data, clinical trials\u003c\/div\u003e\n\u003c\/div\u003e\n        \u003c\/div\u003e\n        \u003csvg class=\"sec-arrow\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\n      \u003c\/summary\u003e\n      \u003cdiv class=\"sec-divider\"\u003e\u003c\/div\u003e\n      \u003cdiv class=\"sec-body\"\u003e\n        \u003cul\u003e\n          \u003cli\u003e\n\u003cstrong\u003eJastreboff AM et al.\u003c\/strong\u003e \"Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.\" \u003cem\u003eN Engl J Med.\u003c\/em\u003e 2023;389:514-526. \u003ca class=\"ref-chip\" href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003e🔗 NEJM\u003c\/a\u003e\n\u003c\/li\u003e\n          \u003cli\u003e\n\u003cstrong\u003eEli Lilly.\u003c\/strong\u003e TRIUMPH-1 Phase 3 Topline Results, 2025. \u003ca class=\"ref-chip\" href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss\" target=\"_blank\" rel=\"noopener\"\u003e🔗 Lilly\u003c\/a\u003e\n\u003c\/li\u003e\n          \u003cli\u003e\n\u003cstrong\u003eZhang Y et al.\u003c\/strong\u003e \"Structural insights into triple agonism at GLP-1R, GIPR and GCGR by retatrutide.\" \u003cem\u003eCell Discovery.\u003c\/em\u003e 2024. \u003ca class=\"ref-chip\" href=\"https:\/\/www.nature.com\/articles\/s41421-024-00700-0\" target=\"_blank\" rel=\"noopener\"\u003e🔗 Nature\u003c\/a\u003e\n\u003c\/li\u003e\n          \u003cli\u003e\n\u003cstrong\u003ePMC Review 2025.\u003c\/strong\u003e \"Retatrutide — A Game Changer in Obesity Pharmacotherapy.\" \u003ca class=\"ref-chip\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12190491\/\" target=\"_blank\" rel=\"noopener\"\u003e🔗 PMC\u003c\/a\u003e\n\u003c\/li\u003e\n        \u003c\/ul\u003e\n      \u003c\/div\u003e\n    \u003c\/details\u003e\n  \u003c\/div\u003e\n\n  \u003c!-- ── Final CTA ─────────────────────────────────────── --\u003e\n  \u003ca class=\"calc-cta\" href=\"https:\/\/mvlabs.mx\/pages\/peptide-calculator\" style=\"text-decoration:none;display:flex;\"\u003e\n    \u003cdiv class=\"calc-cta-text\"\u003e\n\u003cstrong\u003e🧮 MVLabs.mx Peptide Calculator\u003c\/strong\u003e\u003cspan\u003eCalculate exact units and volumes for Retatrutide and 50+ research peptides\u003c\/span\u003e\n\u003c\/div\u003e\n    \u003cdiv class=\"calc-cta-btn\"\u003eOpen Calculator →\u003c\/div\u003e\n  \u003c\/a\u003e\n\n  \u003c!-- ── Product Specs ──────────────────────────────────── --\u003e\n  \u003cdiv style=\"background:#f8fafc;border:1.5px solid #cce8f2;border-radius:14px;padding:20px 24px;margin:24px 0;\"\u003e\n    \u003ch3 style=\"color:#0e4f68;font-size:14px;text-transform:uppercase;letter-spacing:0.07em;margin:0 0 12px;\"\u003eProduct Specifications\u003c\/h3\u003e\n    \u003ctable style=\"width:100%;border-collapse:collapse;font-size:13.5px;\"\u003e\n      \u003ctr\u003e\n\u003ctd style=\"padding:6px 0;color:#456d80;width:40%;\"\u003ePurity\u003c\/td\u003e\n\u003ctd style=\"font-weight:600;color:#0a1e2c;\"\u003e≥99% HPLC\u003c\/td\u003e\n\u003c\/tr\u003e\n      \u003ctr\u003e\n\u003ctd style=\"padding:6px 0;color:#456d80;\"\u003eFormat\u003c\/td\u003e\n\u003ctd style=\"font-weight:600;color:#0a1e2c;\"\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n      \u003ctr\u003e\n\u003ctd style=\"padding:6px 0;color:#456d80;\"\u003eQuantity\u003c\/td\u003e\n\u003ctd style=\"font-weight:600;color:#0a1e2c;\"\u003e10 mg per vial\u003c\/td\u003e\n\u003c\/tr\u003e\n      \u003ctr\u003e\n\u003ctd style=\"padding:6px 0;color:#456d80;\"\u003eSKU\u003c\/td\u003e\n\u003ctd style=\"font-weight:600;color:#0a1e2c;\"\u003eRT10\u003c\/td\u003e\n\u003c\/tr\u003e\n      \u003ctr\u003e\n\u003ctd style=\"padding:6px 0;color:#456d80;\"\u003eStorage\u003c\/td\u003e\n\u003ctd style=\"font-weight:600;color:#0a1e2c;\"\u003e2–8°C · Protect from light\u003c\/td\u003e\n\u003c\/tr\u003e\n      \u003ctr\u003e\n\u003ctd style=\"padding:6px 0;color:#456d80;\"\u003eIntended use\u003c\/td\u003e\n\u003ctd style=\"font-weight:600;color:#b45309;\"\u003eResearch use only — not for human consumption\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003c\/table\u003e\n  \u003c\/div\u003e\n\n  \u003c!-- ── Footnotes ─────────────────────── --\u003e\n  \u003cdiv class=\"reta-footnotes\"\u003e\n    \u003ch4\u003eReferences\u003c\/h4\u003e\n    \u003col class=\"fn-list\"\u003e\n      \u003cli data-n=\"[1]\"\u003eJastreboff AM et al. N Engl J Med. 2023;389:514-526. \u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener\"\u003eDOI\u003c\/a\u003e\n\u003c\/li\u003e\n      \u003cli data-n=\"[2]\"\u003eFinan B et al. Sci Transl Med. 2013. [Dual\/triple agonist rationale]\u003c\/li\u003e\n      \u003cli data-n=\"[3]\"\u003eZhang Y et al. Cell Discovery. 2024. \u003ca href=\"https:\/\/www.nature.com\/articles\/s41421-024-00700-0\" target=\"_blank\" rel=\"noopener\"\u003eNature\u003c\/a\u003e\n\u003c\/li\u003e\n    \u003c\/ol\u003e\n    \u003cp style=\"font-size:11px;color:#456d80;margin-top:16px;\"\u003e© 2026 MVLabs.mx. For research and educational purposes only. Not intended for human consumption. Always consult a licensed healthcare professional. \u003ca href=\"https:\/\/mvlabs.mx\/pages\/peptide-calculator\"\u003ePeptide Calculator\u003c\/a\u003e\u003c\/p\u003e\n  \u003c\/div\u003e\n\n\u003c\/div\u003e\u003c!-- \/reta-page --\u003e","brand":"MV Labs","offers":[{"title":"10 mg","offer_id":44559030976627,"sku":"RT10","price":3200.0,"currency_code":"MXN","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/3577\/6371\/files\/Retadetail2.png?v=1773020778"},{"product_id":"other-example-product-2","title":"CJC + IPA","description":"\u003cdiv style=\"font-family:Arial,sans-serif;max-width:680px;margin:20px 0 24px;border:1px solid #cbd5e1;border-radius:10px;overflow:hidden;\"\u003e\n\u003cdiv style=\"background:#1a3c5e;color:#fff;padding:12px 16px;\"\u003e\n\u003cstrong style=\"font-size:15px;\"\u003eProtocolo de Dosificación\u003c\/strong\u003e\u003cspan style=\"font-size:12px;margin-left:12px;opacity:0.85;\"\u003e2–3 veces al día · Subcutáneo\u003c\/span\u003e\n\u003c\/div\u003e\n\u003cdiv style=\"background:#e8f0f8;padding:10px 16px;font-size:13px;color:#1a3c5e;\"\u003e\n\u003cstrong\u003eReconstitución:\u003c\/strong\u003e 10 mg total (5 mg CJC + 5 mg IPA) + 3 mL BAC Water = 3.33 mg\/mL\u003c\/div\u003e\n\u003ctable style=\"width:100%;border-collapse:collapse;font-size:13px;\"\u003e\n\u003cthead\u003e\u003ctr style=\"background:#2d5a8e;color:#fff;\"\u003e\n\u003cth style=\"padding:8px 10px;text-align:left;\"\u003eFase\u003c\/th\u003e\n\u003cth style=\"padding:8px 10px;text-align:left;\"\u003eDosis\u003c\/th\u003e\n\u003cth style=\"padding:8px 10px;text-align:center;\"\u003eUnidades (U-100)\u003c\/th\u003e\n\u003cth style=\"padding:8px 10px;text-align:center;\"\u003eVolumen (mL)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background:#f8fafc\"\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;\"\u003eEstándar\u003c\/td\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;font-weight:600;color:#1a3c5e;\"\u003e200 mcg CJC + 200 mcg IPA\u003c\/td\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;text-align:center;\"\u003e24 unidades\u003c\/td\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;text-align:center;\"\u003e0.24 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#ffffff\"\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;\"\u003eReducida\u003c\/td\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;font-weight:600;color:#1a3c5e;\"\u003e100 mcg CJC + 100 mcg IPA\u003c\/td\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;text-align:center;\"\u003e12 unidades\u003c\/td\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;text-align:center;\"\u003e0.12 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cdiv style=\"background:#f8fafc;padding:8px 16px;font-size:11px;color:#64748b;\"\u003e⚠️ Solo para investigación. Consulta a un profesional de salud calificado antes de uso.\u003c\/div\u003e\n\u003c\/div\u003e\u003ch2\u003eCJC-1295 + Ipamorelin Blend — Synergistic GH Research Stack\u003c\/h2\u003e\n\u003cp\u003eThis pre-blended combination of CJC-1295 (no DAC, GHRH analog) and Ipamorelin (GHRP\/ghrelin agonist) targets two complementary receptor pathways to produce maximally amplified, pulsatile growth hormone release. This is one of the most widely researched GH-optimizing stacks.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Applications\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eMaximized pulsatile GH release research\u003c\/li\u003e\n\u003cli\u003eAnti-aging and longevity protocols\u003c\/li\u003e\n\u003cli\u003eMuscle anabolism and fat loss combination studies\u003c\/li\u003e\n\u003cli\u003eIGF-1 optimization and connective tissue support\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eReconstitution\u003c\/h3\u003e\n\u003cp\u003eReconstitute with 2 mL BAC water for standard concentration. Use U-100 insulin syringe for dosing.\u003c\/p\u003e\n\n\u003ch3\u003eDosing Protocol (Research Reference)\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eDose:\u003c\/strong\u003e 100 µg each component (CJC + IPA) per injection\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFrequency:\u003c\/strong\u003e 2–3× daily (AM + pre-workout\/bedtime), fasted state\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRoute:\u003c\/strong\u003e Subcutaneous injection\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCycle:\u003c\/strong\u003e 12 weeks on, 4 weeks off\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eStorage\u003c\/h3\u003e\n\u003cp\u003eStore lyophilized at −20°C. After reconstitution, refrigerate at 2–8°C and use within 21 days.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003e⚠️ For research use only.\u003c\/em\u003e\u003c\/p\u003e","brand":"MV Labs","offers":[{"title":"Default Title","offer_id":44438965747827,"sku":null,"price":3200.0,"currency_code":"MXN","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/3577\/6371\/files\/cjcipadetail_1e70ac49-7f64-4c52-b4aa-622a4947c6fe.png?v=1773018046"},{"product_id":"other-example-product-3","title":"GHK-Cu","description":"\u003cdiv style=\"font-family:Arial,sans-serif;max-width:680px;margin:20px 0 24px;border:1px solid #cbd5e1;border-radius:10px;overflow:hidden;\"\u003e\n\u003cdiv style=\"background:#1a3c5e;color:#fff;padding:12px 16px;\"\u003e\n\u003cstrong style=\"font-size:15px;\"\u003eProtocolo de Dosificación\u003c\/strong\u003e\u003cspan style=\"font-size:12px;margin-left:12px;opacity:0.85;\"\u003e1–2 veces al día · Subcutáneo\u003c\/span\u003e\n\u003c\/div\u003e\n\u003cdiv style=\"background:#e8f0f8;padding:10px 16px;font-size:13px;color:#1a3c5e;\"\u003e\n\u003cstrong\u003eReconstitución:\u003c\/strong\u003e 50 mg + 3 mL BAC Water = 16.67 mg\/mL\u003c\/div\u003e\n\u003ctable style=\"width:100%;border-collapse:collapse;font-size:13px;\"\u003e\n\u003cthead\u003e\u003ctr style=\"background:#2d5a8e;color:#fff;\"\u003e\n\u003cth style=\"padding:8px 10px;text-align:left;\"\u003eFase\u003c\/th\u003e\n\u003cth style=\"padding:8px 10px;text-align:left;\"\u003eDosis\u003c\/th\u003e\n\u003cth style=\"padding:8px 10px;text-align:center;\"\u003eUnidades (U-100)\u003c\/th\u003e\n\u003cth style=\"padding:8px 10px;text-align:center;\"\u003eVolumen (mL)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background:#f8fafc\"\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;\"\u003eInicio\u003c\/td\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;font-weight:600;color:#1a3c5e;\"\u003e1 mg\/día\u003c\/td\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;text-align:center;\"\u003e6 unidades\u003c\/td\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;text-align:center;\"\u003e0.06 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#ffffff\"\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;\"\u003eEstándar\u003c\/td\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;font-weight:600;color:#1a3c5e;\"\u003e2 mg\/día\u003c\/td\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;text-align:center;\"\u003e12 unidades\u003c\/td\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;text-align:center;\"\u003e0.12 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f8fafc\"\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;\"\u003eMáximo\u003c\/td\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;font-weight:600;color:#1a3c5e;\"\u003e5 mg\/día\u003c\/td\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;text-align:center;\"\u003e30 unidades\u003c\/td\u003e\n\u003ctd style=\"padding:8px 10px;border-bottom:1px solid #e2e8f0;text-align:center;\"\u003e0.30 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cdiv style=\"background:#f8fafc;padding:8px 16px;font-size:11px;color:#64748b;\"\u003e⚠️ Solo para investigación. Consulta a un profesional de salud calificado antes de uso.\u003c\/div\u003e\n\u003c\/div\u003e\u003ch2\u003eGHK-Cu — Copper Tripeptide Research Compound\u003c\/h2\u003e\n\u003cp\u003eGHK-Cu (Glycyl-L-Histidyl-L-Lysine copper complex) is a naturally occurring copper peptide with potent anti-aging, anti-inflammatory, and regenerative properties. It is extensively studied in dermatology, wound healing, and age-related tissue degeneration research.\u003c\/p\u003e\n\n\u003ch3\u003eMechanism of Action\u003c\/h3\u003e\n\u003cp\u003eGHK-Cu activates over 4,000 genes involved in tissue remodeling, collagen synthesis, antioxidant defense, and stem cell activation. It functions as a chaperone for copper ions critical to enzyme activity and neutralizes reactive oxygen species.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Applications\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eSkin regeneration, wrinkle reduction, and wound healing\u003c\/li\u003e\n\u003cli\u003eHair follicle stimulation and hair loss research\u003c\/li\u003e\n\u003cli\u003eCollagen and elastin synthesis enhancement\u003c\/li\u003e\n\u003cli\u003eAnti-inflammatory and antioxidant research\u003c\/li\u003e\n\u003cli\u003eLung and kidney tissue protection studies\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eReconstitution\u003c\/h3\u003e\n\u003cp\u003eReconstitute 50 mg vial with 5 mL sterile water → \u003cstrong\u003e10 mg\/mL\u003c\/strong\u003e. For topical: dilute further in saline or peptide serum vehicle.\u003c\/p\u003e\n\n\u003ch3\u003eDosing Protocol (Research Reference)\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eSubcutaneous:\u003c\/strong\u003e 1–2 mg daily or every other day\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTopical:\u003c\/strong\u003e 1–5% concentration in appropriate vehicle\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRoute:\u003c\/strong\u003e Subcutaneous injection or topical application\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCycle:\u003c\/strong\u003e 4–12 weeks continuous use\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eStorage\u003c\/h3\u003e\n\u003cp\u003eStore lyophilized at −20°C. After reconstitution, refrigerate at 2–8°C and use within 30 days. Protect from light.\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003e⚠️ For research use only.\u003c\/em\u003e\u003c\/p\u003e","brand":"MV Labs","offers":[{"title":"Default Title","offer_id":44438965780595,"sku":null,"price":1250.0,"currency_code":"MXN","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/3577\/6371\/files\/GHKDetail.png?v=1775057784"},{"product_id":"other-example-product-4","title":"BPC-157","description":"\u003cmeta charset=\"UTF-8\"\u003e\n\u003cstyle\u003e\n:root{--d:#0b3347;--p:#0e4f68;--m:#2590b4;--l:#5ab4cc;--pl:#cce8f2;--ic:#e8f5fa;--t:#0a1e2c;--mu:#456d80;--r:14px}\n*{box-sizing:border-box}.pg{font-family:-apple-system,BlinkMacSystemFont,'Segoe UI',sans-serif;color:var(--t);max-width:880px;margin:0 auto;padding:0 16px 60px;line-height:1.7}\n.pg h1,.pg h2,.pg h3,.pg p,.pg ul,.pg ol,.pg li,.pg a{margin:0 0 10px;font-size:14px}\n.pg h1{font-size:clamp(20px,4vw,32px);font-weight:900;letter-spacing:-.03em;color:var(--d)}\n.pg h2{font-size:17px;font-weight:800;color:var(--d)}\n.pg h3{font-size:14px;font-weight:700;color:var(--p);margin:14px 0 5px}\n.pg a{color:var(--m);text-decoration:underline}\n.hero{background:linear-gradient(135deg,var(--d) 0%,var(--p) 65%,var(--m) 100%);border-radius:var(--r);padding:34px 26px 30px;margin-bottom:22px;color:#fff;position:relative;overflow:hidden}\n.hero::before{content:'';position:absolute;inset:0;background:url(\"data:image\/svg+xml,%3Csvg width='60' height='60' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cg fill='%23ffffff' fill-opacity='0.04'%3E%3Cpolygon points='30,5 55,18 55,42 30,55 5,42 5,18'\/%3E%3C\/g%3E%3C\/svg%3E\");pointer-events:none}\n.badge{display:inline-flex;align-items:center;background:rgba(255,255,255,.15);border:1px solid rgba(255,255,255,.25);border-radius:20px;padding:3px 12px;font-size:11px;font-weight:600;letter-spacing:.06em;text-transform:uppercase;margin-bottom:11px;gap:5px}\n.hero h1{color:#fff;font-size:clamp(21px,4.5vw,34px);font-weight:900;letter-spacing:-.03em;margin:0 0 8px}\n.hero p{opacity:.88;font-size:14px;max-width:520px;margin:0 0 12px}\n.hmeta{display:flex;flew-wrap:wrap;gap:9px;font-size:11px;opacity:.75}\n.warn{background:#fffbeb;border:1.5px solid #fcd34d;border-left:5px solid #b45309;border-radius:var(--r);padding:11px 14px;margin-bottom:18px;font-size:12.5px;color:#92400e;line-height:1.6}\n.warn strong{color:#78350f}\n.stats{display:grid;grid-template-columns:repeat(auto-fit,minmax(115px,1fr));gap:8px;margin:10px 0 14px}\n.sc{background:var(--ic);border:1.5px solid var(--pl);border-radius:10px;padding:11px 9px;text-align:center}\n.sv{font-size:22px;font-weight:900;color:var(--p);line-height:1;margin-bottom:3px}\n.sl{font-size:9px;color:var(--mu);font-weight:600;text-transform:uppercase;letter-spacing:.05em}\n.ss{font-size:8.5px;color:var(--mu);margin-top:2px}\n.sec{background:#fff;border:1.5px solid var(--pl);border-radius:var(--r);margin-bottom:11px;box-shadow:0 2px 5px rgba(11,51,71,.05);overflow:hidden}\n.sec details\u003esummary{display:flex;align-items:center;justify-content:space-between;padding:14px 18px;cursor:pointer;user-select:none;list-style:none;gap:8px}\n.sec details\u003esummary::-webkit-details-marker,.sec details\u003esummary::marker{display:none}\n.shd{display:flex;align-items:center;gap:8px}\n.sic{width:30px;height:30px;border-radius:7px;flex-shrink:0;background:var(--ic);display:flex;align-items:center;justify-content:center;font-size:15px}\n.stt{font-size:13.5px;font-weight:700;color:var(--p)}.sub{font-size:10.5px;color:var(--mu);margin-top:1px}\n.sarr{width:17px;height:17px;flex-shrink:0;color:var(--m);transition:transform .25s}\ndetails[open] .sarr{transform:rotate(180deg)}\n.sbd{padding:0 18px 18px}.sdiv{height:1.5px;background:var(--pl);margin:0 18px 14px}\n.chart{background:var(--ic);border:1.5px solid var(--pl);border-radius:10px;padding:14px 11px;margin:10px o;overflow-x:auto}\n.ct{font-size:10px;font-weight:700;color:var(--mu);text-transform:uppercase;letter-spacing:.06em;margin-bottom:9px}\n.cs{font-size:9px;color:var(--mu);margin-top:5px;text-align:right}\n.tbl{width:100%;border-collapse:collapse;font-size:12px;margin:8px 0}\n.tbl th{background:var(--p);color:#fff;padding:7px 9px;text-align:left;font-size:10px;text-transform:uppercase;letter-spacing:.05em}\n.tbl th:first-child{border-radius:5px 0 0 0}.tbl th:last-child{border-radius:0 5px 0 0}\n.tbl td{padding:6px 9px;border-bottom:1px solid var(--pl);font-size:12px}\n.tbl tr:last-child td{border-bottom:none}.tbl tr:nth-child(even) td{background:var(--ic)}\n.tbl .ph{font-weight:600;color:var(--p)}.tbl .mx td{background:#e0f2fe!important;font-weight:700;color:var(--d)}\n.recon{background:linear-gradient(135deg,var(--d),var(--p));border-radius:10px;padding:14px 16px;color:#fff;margin:10px 0}\n.recon h3{color:#fff;margin-top:0;font-size:11.5px;opacity:.85;text-transform:uppercase;letter-spacing:.07em}\n.rf{font-size:17px;font-weight:800;margin:4px 0;letter-spacing:-.01em}.rd{font-size:11.5px;opacity:.8}\n.cta{background:linear-gradient(135deg,var(--p),var(--m));border-radius:var(--r);padding:18px 20px;display:flex;align-items:center;justify-content:space-between;flex-wrap:wrap;gap:10px;margin:16px 0;text-decoration:none!important}\n.cta-t{color:#fff}.cta-t strong{display:block;font-size:14px;font-weight:800;margin-bottom:2px}\n.cta-t span{font-size:12px;opacity:.85}\n.cta-b{background:#fff;color:var(--p);font-weight:800;font-size:12px;border-radius:8px;padding:7px 14px;white-space:nowrap;flex-shrink:0}\n.chip{display:inline-flex;background:var(--ic);border:1px solid var(--pl);border-radius:20px;padding:2px 8px;font-size:10px;color:var(--mu);text-decoration:none;margin:2px}\n.chip:hover{background:var(--pl);color:var(--p)}\n.fn{border-top:2px solid var(--pl);margin-top:28px;padding-top:16px}\n.fn h4{font-size:10px;text-transform:uppercase;letter-spacing:.08em;color:var(--mu);margin:0 0 9px}\n.fnl{list-style:none;padding:0;margin:0}.fnl li{font-size:10.5px;color:var(--mu);margin-bottom:5px;padding-left:18px;position:relative;line-height:1.5}\n.fnl li::before{content:attr(data-n);position:absolute;left:0;font-weight:700;color:var(--m)}\n.fnl a{color:var(--m)}\n@media(max-width:600px){.hero{padding:22px 14px 18px}.sbd{padding:0 10px 14px}.cta{flex-direction:column}.stats{grid-template-columns:repeat(2,1fr)}}\n\u003c\/style\u003e\n\u003cdiv class=\"pg\"\u003e\n\u003cdiv class=\"hero\"\u003e\n\u003cdiv class=\"badge\"\u003e🔬 Research Reference · MVLabs.mx · México · Repair · GI Protection\u003c\/div\u003e\n\u003ch1\u003eBPC-157\u003c\/h1\u003e\n\u003cp\u003eBPC-157 is a 15-aa cytoprotective peptide derived from human gastric juice. 30+ years of pre-clinical research on tendon healing, GI repair, and anti-inflammatory effects. Available in Mexico.\u003c\/p\u003e\n\u003cdiv class=\"hmeta\"\u003e\n\u003cspan\u003e📋 Research only\u003c\/span\u003e\u003cspan\u003e💊 5 mg\/vial\u003c\/span\u003e\u003cspan\u003e⏱ SC\/IP 2×\/day\u003c\/span\u003e\u003cspan\u003e🇲🇽 México\u003c\/span\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"warn\"\u003e\n\u003cstrong\u003e⚠ Research Use Only \/ Solo Uso de Investigación.\u003c\/strong\u003e All information is for educational and scientific research only. Not approved for human use by FDA or COFEPRIS. For in-vitro and pre-clinical research only. MVLabs.mx · \u003ca href=\"\/pages\/peptide-calculator\"\u003ePeptide Calculator\u003c\/a\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"stats\"\u003e\n\u003cdiv class=\"sc\"\u003e\n\u003cdiv class=\"sv\"\u003e15aa\u003c\/div\u003e\n\u003cdiv class=\"sl\"\u003ePentadecapeptide\u003c\/div\u003e\n\u003cdiv class=\"ss\"\u003eGI-derived\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sc\"\u003e\n\u003cdiv class=\"sv\"\u003e2×\/day\u003c\/div\u003e\n\u003cdiv class=\"sl\"\u003eFrequency\u003c\/div\u003e\n\u003cdiv class=\"ss\"\u003eSC or IP\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sc\"\u003e\n\u003cdiv class=\"sv\"\u003e500\u003c\/div\u003e\n\u003cdiv class=\"sl\"\u003eMax dose (µg)\u003c\/div\u003e\n\u003cdiv class=\"ss\"\u003ePer injection\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sc\"\u003e\n\u003cdiv class=\"sv\"\u003eStable\u003c\/div\u003e\n\u003cdiv class=\"sl\"\u003eGI resistance\u003c\/div\u003e\n\u003cdiv class=\"ss\"\u003eUnique property\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sec\"\u003e\u003cdetails open\u003e\u003csummary\u003e\u003cdiv class=\"shd\"\u003e\n\u003cdiv class=\"sic\"\u003e🧬\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"stt\"\u003eMechanism of Action\u003c\/div\u003e\n\u003cdiv class=\"sub\"\u003eBody Protection Compound · GI and Tissue Repair\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csvg class=\"sarr\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/summary\u003e\u003cdiv class=\"sdiv\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"sbd\"\u003e\n\u003cp\u003eBPC-157 activates multiple pathways: upregulates VEGFR\/FGFR growth factor receptors, activates the NO-cGMP pathway, modulates TNF-α and IL-6, and promotes angiogenesis at injury sites. Remarkably stable in gastric juice — enabling both SC and oral administration in research models.\u003csup class=\"fn\"\u003e[1]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cdiv style=\"display:flex;gap:5px;flex-wrap:wrap;margin-top:6px\"\u003e\u003ca class=\"chip\" href=\"\/pages\/peptide-calculator\"\u003e🧮 Peptide Calculator\u003c\/a\u003e\u003c\/div\u003e\n\u003c\/div\u003e\u003c\/details\u003e\u003c\/div\u003e\n\u003cdiv class=\"sec\"\u003e\u003cdetails\u003e\u003csummary\u003e\u003cdiv class=\"shd\"\u003e\n\u003cdiv class=\"sic\"\u003e📊\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"stt\"\u003eClinical Evidence\u003c\/div\u003e\n\u003cdiv class=\"sub\"\u003ePublished research data\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csvg class=\"sarr\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/summary\u003e\u003cdiv class=\"sdiv\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"sbd\"\u003e\n\u003cp\u003e30+ pre-clinical publications:\u003csup class=\"fn\"\u003e[1,2]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTendon healing: 50% faster Achilles repair in rat models\u003c\/li\u003e\n\u003cli\u003eGI ulcers: healed in 14 days vs 21 days control\u003c\/li\u003e\n\u003cli\u003eAnti-inflammatory: reduced TNF-α and IL-6 at injury sites\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv style=\"display:flex;gap:5px;flex-wrap:wrap\"\u003e\u003ca class=\"chip\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/15159005\/\" target=\"_blank\"\u003e📄 Sikiric et al. 2004\u003c\/a\u003e\u003c\/div\u003e\n\u003c\/div\u003e\u003c\/details\u003e\u003c\/div\u003e\n\u003cdiv class=\"sec\"\u003e\u003cdetails\u003e\u003csummary\u003e\u003cdiv class=\"shd\"\u003e\n\u003cdiv class=\"sic\"\u003e📋\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"stt\"\u003eResearch Dosing Protocol\u003c\/div\u003e\n\u003cdiv class=\"sub\"\u003e⚠ Research reference only — not medical advice\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csvg class=\"sarr\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/summary\u003e\u003cdiv class=\"sdiv\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"sbd\"\u003e\n\u003cdiv class=\"recon\"\u003e\n\u003ch3\u003eReconstitution\u003c\/h3\u003e\n\u003cdiv class=\"rf\"\u003e5 mg + 3 mL BAC Water = 1,667 µg\/mL\u003c\/div\u003e\n\u003cdiv class=\"rd\"\u003e1 U-100 = 16.7 µg · Store 2–8°C · Use within 28 days\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ctable class=\"tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePhase\u003c\/th\u003e\n\u003cth\u003eDose\u003c\/th\u003e\n\u003cth\u003eUnits (U-100)\u003c\/th\u003e\n\u003cth\u003eVolume\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"ph\"\u003eLow\u003c\/td\u003e\n\u003ctd\u003e200 µg\u003c\/td\u003e\n\u003ctd\u003e12 U\u003c\/td\u003e\n\u003ctd\u003e0.12 mL\u003c\/td\u003e\n\u003ctd\u003e2×\/day SC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"ph\"\u003eModerate\u003c\/td\u003e\n\u003ctd\u003e350 µg\u003c\/td\u003e\n\u003ctd\u003e21 U\u003c\/td\u003e\n\u003ctd\u003e0.21 mL\u003c\/td\u003e\n\u003ctd\u003e2×\/day\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr class=\"mx\"\u003e\n\u003ctd class=\"ph\"\u003eMax\u003c\/td\u003e\n\u003ctd\u003e500 µg\u003c\/td\u003e\n\u003ctd\u003e30 U\u003c\/td\u003e\n\u003ctd\u003e0.30 mL\u003c\/td\u003e\n\u003ctd\u003eMax · fasted optional\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ca class=\"cta\" href=\"\/pages\/peptide-calculator\"\u003e\u003cdiv class=\"cta-t\"\u003e\n\u003cstrong\u003e🧮 MVLabs.mx Peptide Calculator\u003c\/strong\u003e\u003cspan\u003eCalculate exact units \u0026amp; volumes — syringe slider included\u003c\/span\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"cta-b\"\u003eOpen Calculator →\u003c\/div\u003e\u003c\/a\u003e\n\u003c\/div\u003e\u003c\/details\u003e\u003c\/div\u003e\n\u003cdiv class=\"sec\"\u003e\u003cdetails\u003e\u003csummary\u003e\u003cdiv class=\"shd\"\u003e\n\u003cdiv class=\"sic\"\u003e⚠️\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"stt\"\u003eSafety Profile\u003c\/div\u003e\n\u003cdiv class=\"sub\"\u003eAdverse event reference\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csvg class=\"sarr\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/summary\u003e\u003cdiv class=\"sdiv\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"sbd\"\u003e\u003cul\u003e\n\u003cli\u003eNo significant adverse effects in 30+ years of pre-clinical research\u003c\/li\u003e\n\u003cli\u003eWell-tolerated via SC, IP, and oral routes in animal models\u003c\/li\u003e\n\u003cli\u003eNo completed human clinical trials\u003c\/li\u003e\n\u003c\/ul\u003e\u003c\/div\u003e\u003c\/details\u003e\u003c\/div\u003e\n\u003cdiv class=\"fn\"\u003e\n\u003ch4\u003eReferences\u003c\/h4\u003e\n\u003col class=\"fnl\"\u003e\n\u003cli data-n=\"[1]\"\u003eSikiric P et al. Stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2011. PMID: 21414019\u003c\/li\u003e\n\u003cli data-n=\"[2]\"\u003eChang CH et al. BPC 157 augments tendon-to-bone healing. J Appl Physiol. 2011. PMID: 21071588\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp style=\"font-size:10px;color:var(--mu);margin-top:10px\"\u003e© 2026 MVLabs.mx · BPC-157 México · Péptidos reparación México · BPC157 investigación · \u003ca href=\"\/pages\/peptide-calculator\"\u003ePeptide Calculator\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MV Labs","offers":[{"title":"Default Title","offer_id":44438965813363,"sku":null,"price":700.0,"currency_code":"MXN","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/3577\/6371\/files\/BPCDetail.png?v=1773017519"}],"url":"https:\/\/mvlabs.mx\/collections\/other-example-products.oembed","provider":"MV Labs","version":"1.0","type":"link"}